VeraCept

DRUG3 trials

Sponsors

Sebela Women's Health Inc.

Conditions

ContraceptionWomen at Risk for Pregnancy

Phase 2

Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception

CompletedNCT02446821

Sebela Women's Health Inc.Contraception

Start: 2015-06-01End: 2019-03-22Updated: 2026-03-03

Phase 3

Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS

Active, not recruitingNCT03633799

Sebela Women's Health Inc.Women at Risk for Pregnancy

Start: 2018-08-22End: 2027-09-22Updated: 2025-08-22

A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)

CompletedNCT03785366

Sebela Women's Health Inc.Women at Risk for Pregnancy

Start: 2018-12-17End: 2024-08-01Updated: 2025-08-15

Related Papers

Five-Year Phase 3 Efficacy and Safety Outcomes With a Low-Dose Copper Intrauterine Device.

2026-02-26

Three-year efficacy, safety, and tolerability outcomes from a phase 3 study of a low-dose copper intrauterine device

Contraception2024-11-223 citations

Efficacy, Safety, and Tolerability of a New Low-Dose Copper and Nitinol Intrauterine Device

Obstetrics and Gynecology2020-03-1312 citations